# Monika E Hegi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7590806/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 147 papers | 36,253 citations | 10956 71 h-index | 9553 142 g-index |
| 168 all docs | 168 docs citations | 168 times ranked | 27880 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcomeâ€"including in elderly patients. Acta Neuropathologica Communications, 2022, 10, 39. | 2.4 | 6 |
| 2 | Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. Cancers, 2022, 14, 2233. | 1.7 | 19 |
| 3 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186. | 12.5 | 826 |
| 4 | The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035. | 0.4 | 3 |
| 5 | Hyperpolarized 13C-glucose magnetic resonance highlights reduced aerobic glycolysis in vivo in infiltrative glioblastoma. Scientific Reports, 2021, 11, 5771. | 1.6 | 13 |
| 6 | BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. Neuro-Oncology, 2021, 23, 1680-1692. | 0.6 | 17 |
| 7 | MGMT testing always worth an emotion. Neuro-Oncology, 2021, 23, 1417-1418. | 0.6 | 2 |
| 8 | Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice. Acta Neuropathologica Communications, 2021, 9, 133. | 2.4 | 7 |
| 9 | An integrated pipeline for comprehensive analysis of immune cells in human brain tumor clinical samples. Nature Protocols, 2021, 16, 4692-4721. | 5.5 | 7 |
| 10 | Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis. Nature Cancer, 2021, 2, 1086-1101. | 5.7 | 39 |
| 11 | Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. Cell, 2020, 181, 1643-1660.e17. | 13.5 | 554 |
| 12 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113. | 0.6 | 543 |
| 13 | CBIO-13. EPIGENETIC DEREGULATION OF NUCLEAR TRANSLOCATION - A NOVEL MECHANISM FOR TREATMENT RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii18-ii18. | 0.6 | 0 |
| 14 | COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT. Neuro-Oncology, 2020, 22, ii27-ii27. | 0.6 | 0 |
| 15 | Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. Molecular Cancer Therapeutics, 2019, 18, 1565-1576. | 1.9 | 11 |
| 16 | The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation. Drug Resistance Updates, 2019, 43, 29-37. | 6.5 | 33 |
| 17 | Improving survival in molecularly selected glioblastoma. Lancet, The, 2019, 393, 615-617. | 6.3 | 32 |
| 18 | MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-Oncology, 2019, 21, 167-178. | 0.6 | 173 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clinical Cancer Research, 2019, 25, 1809-1816. | 3.2 | 94 |
| 20 | Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166. | 3.9 | 298 |
| 21 | The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615. | 3.9 | 76 |
| 22 | In vivo characterization of brain metabolism by <sup>1</sup>H MRS, <sup>13</sup>C MRS and <sup>18</sup>FDG PET reveals significant glucose oxidation of invasively growing glioma cells. International Journal of Cancer, 2018, 143, 127-138. | 2.3 | 16 |
| 23 | Toward methylation-based classification of central nervous system tumors. Neuro-Oncology, 2018, 20, 579-581. | 0.6 | 2 |
| 24 | Glioma epigenetics: From subclassification to novel treatment options. Seminars in Cancer Biology, 2018, 51, 50-58. | 4.3 | 377 |
| 25 | European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329. | 5.1 | 816 |
| 26 | Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology, 2017, 19, 1460-1468. | 0.6 | 213 |
| 27 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 2017, 19, 1119-1126. | 0.6 | 107 |
| 28 | Evidence-based management of adult patients with diffuse glioma â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e430-e431. | 5.1 | 5 |
| 29 | Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step?. Neuro-Oncology Practice, 2017, 4, 241-247. | 1.0 | 13 |
| 30 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. JAMA - Journal of the American Medical Association, 2017, 318, 2306. | 3.8 | 1,619 |
| 31 | Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity. Oncotarget, 2017, 8, 110490-110502. | 0.8 | 29 |
| 32 | Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget, 2016, 7, 15018-15032. | 0.8 | 62 |
| 33 | Current management of low-grade gliomas. Current Opinion in Neurology, 2016, 29, 782-788. | 1.8 | 26 |
| 34 | Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806. | 3.2 | 105 |
| 35 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2016, 17, 1521-1532. | 5.1 | 396 |
| 36 | Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1â€‰T. NMR in Biomedicine, 2016, 29, 1577-1589. | 1.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 2016, 34, 3107-3108. | 0.8 | 2 |
| 38 | LTBK-01: PROSPECTIVE, MULTI-CENTER PHASE III TRIAL OF TUMOR TREATING FIELDS TOGETHER WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2016, 18, i1-i1. | 0.6 | 18 |
| 39 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2016, 34, 731-739. | 0.8 | 159 |
| 40 | Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. Journal of Molecular Diagnostics, 2016, 18, 350-361. | 1.2 | 90 |
| 41 | WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. Oncogene, 2016, 35, 12-21. | 2.6 | 114 |
| 42 | Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison. Scientific Reports, 2015, 5, 15375. | 1.6 | 17 |
| 43 | CSIG-05THE UBIQUITIN SPECIFIC PEPTIDASE 15 (USP15) SUPPRESSES PROLIFERATION OF HUMAN GLIOBLASTOMA CELL LINES VIA STABILIZATION OF HECTD1 E3 LIGASE. Neuro-Oncology, 2015, 17, v67.1-v67. | 0.6 | 0 |
| 44 | Mir-21â€“Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. Journal of Neuroscience, 2015, 35, 15097-15112. | 1.7 | 53 |
| 45 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA - Journal of the American Medical Association, 2015, 314, 2535. | 3.8 | 982 |
| 46 | Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 2015, 16, 16. | 3.8 | 82 |
| 47 | Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-Oncology, 2015, 17, 708-717. | 0.6 | 191 |
| 48 | Withholding temozolomide in glioblastoma patients with unmethylatedMGMTpromoterâ€”still a dilemma?: Table 1.. Neuro-Oncology, 2015, 17, 1425-1427. | 0.6 | 78 |
| 49 | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 2015, 17, 1064-1075. | 0.6 | 485 |
| 50 | GENETIC AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX GENE SIGNATURE IN GLIOBLASTOMA. Neuro-Oncology, 2014, 16, iii8-iii8. | 0.6 | 0 |
| 51 | EG-05 * COMBINATION OF GENE COPY GAIN AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX-SIGNATURE IN GLIOBLASTOMA. Neuro-Oncology, 2014, 16, v75-v76. | 0.6 | 0 |
| 52 | Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2014, 32, 1634-1635. | 0.8 | 2 |
| 53 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1100-1108. | 5.1 | 800 |
| 54 | MGMT testingâ€”the challenges for biomarker-based glioma treatment. Nature Reviews Neurology, 2014, 10, 372-385. | 4.9 | 454 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. Journal of Clinical Oncology, 2014, 32, 2003-2003. | 0.8 | 13 |
| 56 | Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, The, 2013, 14, e370-e379. | 5.1 | 167 |
| 57 | The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Neuro-Oncology, 2013, 15, 269-278. | 0.6 | 79 |
| 58 | Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology, 2013, 31, 4085-4091. | 0.8 | 820 |
| 59 | Epigenetics and Brain Cancer. , 2013, , 21-40. | | 0 |
| 60 | Molecular characterization leads the way. Nature Reviews Clinical Oncology, 2013, 10, 69-70. | 12.5 | 11 |
| 61 | Molecular insights into brain tumors. Current Opinion in Neurology, 2013, 26, 678-680. | 1.8 | 1 |
| 62 | In search of molecular markers of glioma in elderly patients. Nature Reviews Neurology, 2013, 9, 424-425. | 4.9 | 9 |
| 63 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. Journal of Clinical Oncology, 2013, 31, LBA2009-LBA2009. | 0.8 | 28 |
| 64 | Individualized Targeted Therapy for Glioblastoma. Cancer Journal (Sudbury, Mass ), 2012, 18, 40-44. | 1.0 | 64 |
| 65 | DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro-Oncology, 2012, 14, 701-711. | 0.6 | 46 |
| 66 | Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 2012, 14, iv100-iv108. | 0.6 | 154 |
| 67 | Epidermal growth factor receptor. Current Opinion in Neurology, 2012, 25, 774-779. | 1.8 | 79 |
| 68 | EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro-Oncology, 2012, 14, 1503-1510. | 0.6 | 58 |
| 69 | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 916-926. | 5.1 | 1,075 |
| 70 | New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. European Journal of Cancer, 2012, 48, 1176-1184. | 1.3 | 161 |
| 71 | MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 2012, 124, 547-560. | 3.9 | 274 |
| 72 | EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. European Journal of Cancer, Supplement, 2012, 10, 20-26. | 2.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Treatment options in elderly patients with glioblastoma â€“ Authors' reply. Lancet Oncology, The, 2012, 13, e461-e462. | 5.1 | 0 |
| 74 | A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature. PLoS ONE, 2012, 7, e41522. | 1.1 | 82 |
| 75 | A safety runâ€in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer, 2012, 118, 5601-5607. | 2.0 | 112 |
| 76 | Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma. Current Neurology and Neuroscience Reports, 2012, 12, 302-307. | 2.0 | 21 |
| 77 | Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 2012, 123, 841-852. | 3.9 | 77 |
| 78 | Alkylpurineâ€“DNAâ€“N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. Journal of Clinical Investigation, 2012, 122, 253-266. | 3.9 | 140 |
| 79 | Expression of O6-methylguanine-DNA methyltransferase in childhood medulloblastoma. Journal of Neuro-Oncology, 2011, 103, 59-69. | 1.4 | 12 |
| 80 | Current concepts and management of glioblastoma. Annals of Neurology, 2011, 70, 9-21. | 2.8 | 380 |
| 81 | The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro-Oncology, 2011, 13, 736-747. | 0.6 | 92 |
| 82 | Extent and Patterns ofMGMTPromoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres. Clinical Cancer Research, 2011, 17, 255-266. | 3.2 | 75 |
| 83 | Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinibâ€”A Phase II Trial. Molecular Cancer Therapeutics, 2011, 10, 1102-1112. | 1.9 | 170 |
| 84 | Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival. Journal of Neuropathology and Experimental Neurology, 2010, 69, 729-736. | 0.9 | 76 |
| 85 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nature Reviews Neurology, 2010, 6, 39-51. | 4.9 | 644 |
| 86 | Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 2010, 120, 585-592. | 3.9 | 127 |
| 87 | MGMT promoter methylation in malignant gliomas. Targeted Oncology, 2010, 5, 161-165. | 1.7 | 66 |
| 88 | Radiotherapy Suppresses Angiogenesis in Mice through TGF-Î²RI/ALK5-Dependent Inhibition of Endothelial Cell Sprouting. PLoS ONE, 2010, 5, e11084. | 1.1 | 68 |
| 89 | Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2010, 28, 2712-2718. | 0.8 | 389 |
| 90 | Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2010, 28, e696-e697. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. Future Oncology, 2010, 6, 1407-1414. | 1.1 | 23 |
| 92 | Neuro-oncology, a decade of temozolomide and beyond. Expert Review of Anticancer Therapy, 2010, 10, 1675-1677. | 1.1 | 19 |
| 93 | Combining Chromosomal Arm Status and Significantly Aberrant Genomic Locations Reveals New Cancer Subtypes. Cancer Informatics, 2009, 7, CIN.S2144. | 0.9 | 0 |
| 94 | Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia. PLoS ONE, 2009, 4, e5947. | 1.1 | 95 |
| 95 | MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 2009, 27, 5881-5886. | 0.8 | 232 |
| 96 | Tenascin-C Is a Novel RBPJÎº-Induced Target Gene for Notch Signaling in Gliomas. Cancer Research, 2009, 69, 458-465. | 0.4 | 122 |
| 97 | Epigenetic Deregulation of DNA Repair and Its Potential for Therapy. Clinical Cancer Research, 2009, 15, 5026-5031. | 3.2 | 54 |
| 98 | RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study. BMC Cancer, 2009, 9, 308. | 1.1 | 83 |
| 99 | Elevated levels of MICâ€1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. International Journal of Cancer, 2009, 125, 2624-2630. | 2.3 | 80 |
| 100 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466. | 5.1 | 6,451 |
| 101 | Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. International Journal of Cancer, 2008, 123, 1215-1218. | 2.3 | 20 |
| 102 | Antiâ€O6â€Methylguanineâ€Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*. Brain Pathology, 2008, 18, 520-532. | 2.1 | 189 |
| 103 | Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, The, 2008, 9, 29-38. | 5.1 | 487 |
| 104 | Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma. Journal of Molecular Diagnostics, 2008, 10, 332-337. | 1.2 | 168 |
| 105 | Correlation of O<sup>6</sup>-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. Journal of Clinical Oncology, 2008, 26, 4189-4199. | 0.8 | 725 |
| 106 | Combined Lysophosphatidic Acid/Platelet-Derived Growth Factor Signaling Triggers Glioma Cell Migration in a Tenascin-C Microenvironment. Cancer Research, 2008, 68, 6942-6952. | 0.4 | 38 |
| 107 | Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments. Clinical Cancer Research, 2008, 14, 957-960. | 3.2 | 125 |
| 108 | Stem Cellâ€"Related â€œSelf-Renewalâ€•Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma. Journal of Clinical Oncology, 2008, 26, 3015-3024. | 0.8 | 631 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Methylguanine Methyltransferase Testing in Glioblastoma: When and How?. Journal of Clinical Oncology, 2007, 25, 1459-1460. | 0.8 | 51 |
| 110 | Endothelin Receptor Type B Counteracts Tenascin-Câ€“Induced Endothelin Receptor Type Aâ€“Dependent Focal Adhesion and Actin Stress Fiber Disorganization. Cancer Research, 2007, 67, 6163-6173. | 0.4 | 51 |
| 111 | Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. Journal of Clinical Oncology, 2007, 25, 4127-4136. | 0.8 | 474 |
| 112 | MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?. Disease Markers, 2007, 23, 97-104. | 0.6 | 51 |
| 113 | Targeting brain-tumor stem cells. Nature Biotechnology, 2007, 25, 193-194. | 9.4 | 70 |
| 114 | Neuro-oncology: oligodendroglioma and molecular markers. Lancet Neurology, The, 2007, 6, 10-12. | 4.9 | 6 |
| 115 | Recent developments in the use of chemotherapy in brain tumours. European Journal of Cancer, 2006, 42, 582-588. | 1.3 | 108 |
| 116 | Correlative studies in neuro-oncology trials: Should they influence treatment?. Current Oncology Reports, 2006, 8, 54-57. | 1.8 | 5 |
| 117 | Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors. Cancer, 2006, 107, 162-170. | 2.0 | 57 |
| 118 | Management of malignant glioma: steady progress with multimodal approaches. Neurosurgical Focus, 2006, 20, E3. | 1.0 | 65 |
| 119 | Changing Paradigmsâ€”An Update on the Multidisciplinary Management of Malignant Glioma. Oncologist, 2006, 11, 165-180. | 1.9 | 357 |
| 120 | Optimal role of temozolomide in the treatment of malignant gliomas. Current Neurology and Neuroscience Reports, 2005, 5, 198-206. | 2.0 | 168 |
| 121 | Genetic Alterations in Brain Tumors Following 1,3-Butadiene Exposure in B6C3F1 Mice. Toxicologic Pathology, 2005, 33, 307-312. | 0.9 | 11 |
| 122 | MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine, 2005, 352, 997-1003. | 13.9 | 6,573 |
| 123 | Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide. Clinical Cancer Research, 2004, 10, 1871-1874. | 3.2 | 1,014 |
| 124 | Differential Gene Expression Analysis Reveals Activation of Growth Promoting Signaling Pathways by Tenascin-C. Cancer Research, 2004, 64, 7377-7385. | 0.4 | 81 |
| 125 | INK4a/Arf is required for suppression of EGFR/Î”EGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma. Oncogene, 2004, 23, 6854-6863. | 2.6 | 9 |
| 126 | Prognostic factors for low-grade gliomas. Seminars in Oncology, 2003, 30, 23-28. | 0.8 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Research, 2003, 63, 6613-25. | 0.4 | 196 |
| 128 | Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene, 2002, 21, 4212-4219. | 2.6 | 145 |
| 129 | Quantitative real-time PCR does not show selective targeting of p14ARF but concomitant inactivation of both p16INK4A and p14ARF in 105 human primary gliomas. Oncogene, 2001, 20, 1103-1109. | 2.6 | 63 |
| 130 | p73 is not Mutated in Meningiomas as Determined with a Functional Yeast Assay but p73 Expression Increases with Tumor Grade. Brain Pathology, 2001, 11, 296-305. | 2.1 | 27 |
| 131 | p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene, 2000, 19, 3816-3822. | 2.6 | 129 |
| 132 | Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. Oncogene, 2000, 19, 5329-5337. | 2.6 | 12 |
| 133 | No Complementation Between TP53 or RBâ€1 and vâ€src in Astrocytomas of GFAPâ€vâ€src Transgenic Mice. Brain Pathology, 1999, 9, 627-637. | 2.1 | 15 |
| 134 | Functional analyses of a uniquep53 germline mutant (y236?) associated with a familial brain tumor syndrome. , 1999, 82, 17-22. | | 5 |
| 135 | The mouse ERG before and after light damage is independent of p53. Documenta Ophthalmologica, 1998, 96, 311-320. | 1.0 | 10 |
| 136 | Determination of p53 Mutations, EGFR Overexpression, and Loss of p16 Expression in Pediatric Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 782-789. | 0.9 | 81 |
| 137 | Hemizygous or homozygous deletion of the chromosomal region containing thep16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. , 1997, 73, 57-63. | | 48 |
| 138 | Familial Brain Tumour Syndrome Associated with a p53 Germline Deletion of Codon 236. Brain Pathology, 1995, 5, 15-23. | 2.1 | 32 |
| 139 | Identical Mutations of the p53 Tumor Suppressor Gene in the Gliomatous and the Sarcomatous Components of Gliosarcomas Suggest a Common Origin from Glial Cells. Journal of Neuropathology and Experimental Neurology, 1995, 54, 651-656. | 0.9 | 130 |
| 140 | Hepatic and pulmonary carcinogenicity of methylene chloride in mice: a search for mechanisms. Toxicology, 1995, 102, 73-81. | 2.0 | 17 |
| 141 | Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Research, 1994, 54, 6257-64. | 0.4 | 75 |
| 142 | Comparison of pulmonaryO6-methylguanine dna adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Molecular Carcinogenesis, 1993, 8, 177-185. | 1.3 | 72 |
| 143 | Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis, 1993, 14, 803-810. | 1.3 | 83 |
| 144 | Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator. Carcinogenesis, 1993, 14, 145-149. | 1.3 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science, 1992, 258, 1148-1152. | 6.0 | 506 |
| 146 | No measurable increase in thymidine glycol or 8-hydroxydeoxyguanosine in liver DNA of rats treated with nafenopin or choline-devoid low-methionine diet. Mutation Research - Reviews in Genetic Toxicology, 1990, 238, 325-329. | 3.0 | 41 |
| 147 | Detection by 32P-postlabeling of thymidine glycol in Î³-irradiated DNA. Carcinogenesis, 1989, 10, 43-47. | 1.3 | 49 |